If you have been reading about 稳定性 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-12. Numbers and descriptions here follow the published literature rather than marketing material.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
=== Extractable nuclear antigens === Extractable nuclear antigens (ENA) are a group of autoantigens that were originally identified as antibody targets in people with autoimmune disorders. They are termed ENA because they can be extracted from the cell nucleus with saline. The ENAs consist of ribonucleoproteins and non-histone proteins, named by either the name of the donor who provided the prototype serum (Sm, Ro, La, Jo), or the name of the disease setting in which the antibodies were found (SS-A, SS-B, Scl-70).
The content of a collective agreement must include terms for an expiry date no longer than 4 years (even if the parties want an ongoing agreement), a dispute resolution clause, a term for employees to make "individual flexibility agreements" (so long as employees are "better off overall"), and a term on consultation on any "major workplace changes" that could impact employees or change hours of work. To assist, the Fair Work Regulations 2009 Schedule 2.3 prescribes a model consultation term. Under section 172, other negotiated content can be anything "pertaining to the relationship between an employer" and "employees", or unions, payroll deductions from wages for union membership dues, and how the agreement will operate. Several court decisions have unduly limited what counts as pertaining to the employment relationship, including not regulating trading hours as opposed to working time, how to deal with surpluses in a defined benefit superannuation fund, whether money was transferred to a union-controlled super-fund, and constraints on employing contract labour as opposed to equal treatment. Even more, the law restricts agreements on union rights of entry, varying restrictions on strike action, and terms requiring employers pay bargaining service fees for non-union members. Once made, an agreement covers all employees it is expressed to, and the agreement is legally binding with civil remedies for breach, with the right of the employer, any employee, and the union having standing to sue in federal court.
== See also == Arnault Tzanck Blood transfusion in Sri Lanka Young blood transfusion, a pseudoscientific practice involving the transfusion of blood taken from young donors to older recipients that is claimed to have health benefits Transdifferentiation AIDS
Although they vary in particulars, polymyositis, dermatomyositis and inclusion body myositis are idiopathic inflammatory myopathies (IIM) primarily characterized by chronic inflammation of human skeletal muscle tissue that ultimately causes the necrosis of muscle cells. This degeneration leads to muscle tissue wasting, weakness and fatigue among other serious effects. Until recently, exercise has been avoided as a type of therapy, and even forbidden due to the risk of triggering or amplifying inflammation. However, several studies have been conducted to test this assumption and have shown that aerobic exercise as well as resistance training can maintain and even improve the quality of life for IIM-affected individuals without increased inflammatory response.
Sources: en.wikipedia.org
== Chemistry == Several chemical factors affect the ionophore activity. The activity of an ionophore-metal complex depends on its geometric configuration and the coordinating sites and atoms which create coordination environment surrounding the metal center. This affects the selectivity and affinity towards a certain ion. Ionophores can be selective to a particular ion but may not be exclusive to it. Ionophores facilitate the transport of ions across biological membranes most commonly via passive transport, which is affected by lipophilicity of the ionophore molecule. The increase in lipophilicity of the ionophore-metal complex enhances its permeability through lipophilic membranes. The hydrophobicity and hydrophilicity of the complex also determines whether it will slow down or ease the transport of metal ions into cell compartments. The reduction potential of a metal complex influences its thermodynamic stability and affects its reactivity. The ability of an ionophore to transfer ions is also affected by the temperature.
On 4 March, at the Extraordinary Arab Summit in Cairo on Developments in the Palestinian Issue, Arab leaders adopted a $53 billion plan proposed by Egypt that did not involve displacing Palestinians from the Strip. The plan was to create an interim committee of "independent, professional Palestinian technocrats" to govern Gaza to prepare for the Palestinian Authority’s return. Hamas said that it would not bring its own candidates to the proposed governing committee but that it would need to give its permission in regards to the committee’s tasks, members and agenda. Mahmoud Abbas said that he would be prepared to hold elections, which Hamas welcomed. The summit released an AI-enhanced presentation showing modern housing developments, as well as blueprints for resorts and attractions. The plan was to seek international funding. The plan outlines a six-month phase of recovery providing temporary housing for 1.5 million displaced Palestinians within seven sites in Gaza, followed by a two-stage reconstruction program: a two-year first stage of $20 billion and a 2.5 year second stage of $30 billion. The New York Times reported the funding for the plan remains unclear as Gulf states will be reluctant to invest in rebuilding Gaza only to see it destroyed again if violence returns. The Israeli foreign ministry said the plan had "outdated" outlooks and rejected the plan's dependence on the Palestinian Authority, adding that Hamas would be given power by the plan.
=== Electrophysiology === Electroencephalography (EEG) is not routinely used as a primary test for Alzheimer's disease but may assist in the differential diagnosis of cognitive impairment by helping exclude metabolic encephalopathies, Creutzfeldt–Jakob disease, epileptic disorders, and some atypical dementias. EFNS Quantitative EEG studies consistently demonstrate slowing of the dominant posterior rhythm, increased theta and delta activity, reduced alpha power, and disrupted functional connectivity, changes that correlate with disease severity and cognitive decline. Expert consensus considers resting-state EEG a promising non-invasive test for research, patient stratification, and monitoring in clinical trials, although it is not recommended as a substitute for established imaging or fluid biomarkers. Event-related potentials (ERPs), particularly the P300 component, have also been extensively investigated. Meta-analyses show significantly reduced P300 amplitude in patients with Alzheimer's disease, while prolonged latency has been reported in many studies, reflecting impaired cognitive processing. Despite these findings, variability between recording protocols has limited the routine clinical use of ERP measures, and they remain primarily research tools.
Sources: en.wikipedia.org
=== Pharmacology === Cannabinoids are administered via smoking, vaporizing, oral ingestion, transdermal patch, intravenous injection, sublingual absorption, or rectal suppository. Most are metabolized in the liver by cytochrome P450 enzymes, mainly CYP 2C9. Inhibiting CYP 2C9 can extend intoxication. Δ9-THC is metabolized to 11-hydroxy-Δ9-THC and then 9-carboxy-THC, detectable in the body for weeks due to their lipophilic nature and storage in fat. The entourage effect suggests that terpenes modulate cannabinoid effects.
=== Government === Official U.S. Government web portal – gateway to government sites House – official website of the United States House of Representatives Senate – official website of the United States Senate White House – official website of the president of the United States Supreme Court – official website of the Supreme Court of the United States
=== American Hospital Association (AHA) === The American Hospital Association has expressed concern that FDA's proposal to classify LDTs as medical devices exceeds the agency's appropriate regulatory scope, urging the FDA to continue to apply its enforcement discretion to hospital and health system LDTs and defer regulation of these tests mainly to CMS's strict CLIA oversight, the CAP accreditation and state law. The organization has called on Congress to either exclude hospitals and health systems from this device classification framework or to modernize LDT oversight in a way that promotes innovation while maintaining test accessibility, safety, and effectiveness.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.